Ubs Group Ag Protagonist Therapeutics, Inc Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$257 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$252 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$238 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$185 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$139 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.15B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...